This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as Leqembi, in October 2025.
A new study from the Alzheimer Society of Canada is ringing alarm bells about the increasing number of people dealing with dementia. Called "The Landmark Study: The Many Faces of Dementia in Canada," ...
Popular joint supplement glucosamine may speed Alzheimer's progression, raising urgent questions for millions.
Health Canada has approved Eli Lilly’s donanemab (Kisunla™) for adults with mild cognitive impairment or early-stage Alzheimer’s disease, making it the country’s second disease-modifying therapy. The ...
NKGen Biotech activates two new clinical trial sites for Alzheimer's treatment, enhancing patient access and recruitment for troculeucel therapy. NKGen Biotech, Inc. has announced the activation of ...
June is Brain Awareness and Alzheimer’s Month, which is a good time to review news and advancements on the subject of Alzheimer’s disease, especially as it has been estimated that 6.9 million ...
ST. LOUIS--(BUSINESS WIRE)--People in Canada concerned about their memory loss or their loved ones’ issues now have a new option to aid in diagnosis. Toronto Memory Program (TMP) is the first clinic ...
The IG Wealth Management Bancroft Alzheimer’s Walk is coming to town again this year on May 31 at Millennium Park. Walks will also be taking place all weekend long in ...
Health Canada has approved Eli Lilly’s donanemab, branded as Kisunla, as the country’s second Alzheimer’s drug shown to slow disease progression. The therapy targets amyloid plaques and is intended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results